Accel Research Sites Network

Accel Research Sites, based in the US, specializes in enhancing patient access to clinical trials and improving participation across diverse therapeutic areas through dedicated research facilities and community collaborations. Accel Research Sites is engaged in facilitating clinical trial participation for a wide range of patients. The company was founded in 1998 and is headquartered in Lake Mary, US. The leadership team includes CEO Bill Holt, Lora Parahovnik, and Marshall Nash.

Notably, in July 2023, Accel Research Sites was acquired by Alcanza Clinical Research, which aims to leverage the acquisition to expand its network and patient reach, particularly in the Southeast US. Accel Research Sites operates numerous dedicated clinical research facilities throughout the US, focusing on providing health education and facilitating participation in clinical trials. The company collaborates with medical providers and community organizations to ensure that clinical research is accessible, particularly for underrepresented communities. Their services cater to both patients seeking innovative treatment options and sponsors looking to conduct patient-centric studies.

Accel Research Sites earns revenue primarily through its engagements with clinical trial sponsors, conducting research services that include patient recruitment, data collection, and study management. Revenue is derived from the complexity of the trials and the number of enrolled participants, aligning its financial model with the successful execution of clinical studies. In July 2023, Accel Research Sites was acquired by Alcanza Clinical Research, which will utilize the acquisition to enhance its capabilities in the Southeast US. The integration is expected to expand access to clinical trials and improve patient outreach in this region.

There are plans to develop new initiatives aimed at increasing participation in clinical research, although specific product launches or release dates have not been disclosed.